Drug Trial Radar · NCT07948109
YSCH-01 for Recurrent or Progressive Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shanghai Yuansong Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.
Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma)
- Progressive Glioblastoma
- Recurrent Glioblastoma
Interventions
YSCH-01Drug
After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLT)Time frame: 21 days after the first dose and 21 days after the second dose
- Safety and tolerability assessed by Adverse Events (AEs)Time frame: From first dose up to 28 days after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.